Omeros (NASDAQ:OMER) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report released on Friday morning.

Several other equities analysts have also recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Thursday, February 20th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Price Performance

Shares of Omeros stock opened at $9.10 on Friday. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The company has a 50-day simple moving average of $8.70 and a two-hundred day simple moving average of $7.37. The stock has a market capitalization of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently added to or reduced their stakes in OMER. Truvestments Capital LLC increased its position in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP acquired a new position in Omeros during the 4th quarter worth approximately $46,000. BNP Paribas Financial Markets increased its position in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its position in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 4,404 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.